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Abstract
Health economists have studied the determinants of the expected value of health status as a function of medical
and non-medical inputs, often finding small marginal effects of the former. However, medical inputs may have an
additional benefit in the form of a reduced variability of health status. Using the standard deviation of life
expectancy in 24 OECD countries between 1960 and 2005, a 10 percent increase of health care expenditure is
associated with a decrease of an estimated 0.42 percent. Willingness to pay for such a reduction of uncertainty
may well exceed the extra health care expenditure in the United States and Switzerland. This implies that even in
these two countries with very high health care expenditure per capita, flat-of-the-curve medicine need not be
wasteful.
JEL-Classification: I12, J10
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Introduction
Industrial countries have been spending a rising share of
their economic resources on health care. From 1960 to
2004 health care expenditure (HCE) of OECD countries
increased from 3.8 percent of GDP to 8.9 percent on
average. Over the same period, health outcomes mea-
sured by average life expectancy at birth improved from
68.4 to 78.5 years. However, this increase has slowed
recently. In the United States e.g., it has been 0.19 per-
cent p.a. between 1980 and 2004, down from 0.3
between 1960 and 1980. Since HCE continued to grow
at a rate of 7.7 percent p.a. between 1980 and 2004, this
has often been interpreted as evidence of decreasing
marginal returns ("flat-of-the-curve medicine"; [1,2]),
raising the question of why citizens and governments
failed to reallocate resources away from medicine.
However, calling for such reallocation may be prema-
ture on at least two accounts. First, several studies based
on individual health care expenditure data find that
marginal returns to HCE still outweigh its marginal cost
(see e.g. [3-5]; for an overview see [6]). This would
explain why, in countries where individual willingness to
pay for medical services tends to prevail over political
considerations of cost control (such as the United
States, the Netherlands, and Switzerland), the share of
HCE in the GDP keeps increasing. Second, the implicit
assumption that individuals only value changes in the
expected value of health status is open to criticism. If
people are risk-averse with regard to their health, they
value a reduction in the variance of health status even if
its expected value does not change. Thus, judging the
benefits of HCE by its marginal product in terms of
expected health (as traditionally done in studies of the
production of health) possibly neglects the willingness
to pay of risk-averse individuals for reduced uncertainty
surrounding their health status.
Following up on this second aspect, this study seeks to
determine whether the marginal cost in terms of HCE
matches its marginal benefit if the reduction in uncer-
tainty surrounding life expectancy is accounted for. In
order to do this, we will proceed as follows. First, a con-
ventional production function with life expectancy as
the dependent variable is reestimated to verify that the
countries of our sample are characterized by flat-of-the-
curve medicine. Second, we examine whether a reduc-
tion of uncertainty surrounding life expectancy indeed
occurred over the past 46 years. Third, based on the
econometric estimation of an appropriately modified
health production function we determine the relative
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contribution of medical and non-medical factors to
reduced uncertainty. Finally, we compare the marginal
cost of HCE with its marginal benefit in terms of will-
ingness to pay for reduced uncertainty.
We find HCE as well as GDP to be significant deter-
minants of the variance of health status. A 10 percent
increase of HCE is estimated to lead to a 0.42 percent
reduction of the standard deviation of life years.
Furthermore, according to our calculations willingness
to pay both in the United States and Switzerland for
such a reduction exceeds the extra HCE, implying that
additional HCE may be worth its cost as “real insur-
ance”, bringing back health status to normal when ill-
ness strikes. Hence, flat-of-the-curve medicine need not
be wasteful.
Our study is closely related to the empirical literature
on the production of health which uses aggregated
health care expenditure data (e.g. [7-10], and [11]).
Aggregated data have the advantage of providing panel
measurements with variation between countries. How-
ever, rather than assessing the contribution of inputs
exclusively to the expected value of health status, this
study estimates their impact on the variability of health
status as well. Furthermore, this work complements stu-
dies conducted on the individual level deriving willing-
ness-to-pay values for health risk reductions either from
experiments (see e.g. [12]) or from utility-theoretic mod-
els (see e.g. [13]).
Theoretical background
The basic hypothesis underlying this work is that indivi-
duals have preferences with regard to health profiles
that are reflected in survival curves and their develop-
ment over time. As a convenient starting point, consider
the two hypothetical health profiles of Figure 1. Health
profile A presumably represents the ideal of western
lifestyle, living in perfect health followed by sudden
death, indicated by a health status of zero ([14]). In con-
trast, health profile B represents an alternative where
health status deteriorates with age but remains positive
up to a higher age, indicating survival. The two profiles
can also be interpreted as reflecting the probability of
being in perfect health, which starts at 100 percent and
stays there (profile A) or decreases with age (profile B).
Thus, they represent cumulative distribution functions
(cdfs), defined over the absence of death rather than
(say) wealth. Even if profile B should have higher
expected value, they can still be ranked in terms of sec-
ond-order stochastic dominance (see e.g [15], ch. 2.5).
In the present case, the triangle-like area above profile B
(indicating the cumulative difference between the two
cdfs) exceeds the extra area below profile B. In this
event, an individual who is risk-averse with regard to
health status prefers profile A. He or she has a positive
willingness-to-pay (WTP) for living in a country with a
health profile A rather than B.
Health profiles of this type are not available at this
time. However, if individuals are successful in moving
from profile B to the more rectangular profile A, they
should in the aggregate exhibit an increasingly rectangu-
lar survival curve because survival constitutes the neces-
sary (but not sufficient) condition for being in perfect
health. Therefore, variability of age at death will be used
as an indicator of uncertainty surrounding health status.
Various indicators of variability of age at death (VAD)
are used in the literature such as the interquartile range
([16]), the Gini coefficient ([17] and [18]), and the stan-
dard deviation ([19]). Regardless of choice of indicator,
these studies document a secular decline in VAD for
industrial countries, albeit at a somewhat reduced rate
during the most recent decades. This development is
tantamount to a rectangularization of the survival curve
(see Figure 2 showing the case of Sweden). In keeping
with the argument above, it is interpreted as evidence of
Figure 1 Ranking of two health profiles.
Figure 2 Rectangularization of the survival curve in Sweden.
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individual’s improved control over their health status.
Note also that this improvement increasingly is reflected
in the neighborhood of the nearly vertical segment of
the nearly rectangular survival curve, calling for a special
focus on the VAD of the elderly.
What this evidence is silent about is how individuals
might have achieved this added control. In analogy with
the production of health literature, it would be interest-
ing to know whether the major contribution came from
medical or non-medical inputs. To the authors’ knowl-
edge, there is only one study that relates a measure of
VAD to medical and non-medical inputs ([20]). Due to
data limitations, [20] performs but a cross-sectional
regression for 1982 including 17 OECD countries. He
relates public HCE, total HCE, GDP per capita, and a
measure of income inequality (the share of the bottom
quintile in national income) to the Gini coefficient of
mortality. Public HCE has the expected negative impact
on VAD but remains insignificant. Surprisingly, total
HCE has a positive impact, whereas a higher GDP per
capita and less income inequality are associated with
lower VAD. However, the Gini coefficient is not transla-
tion independent (i.e. it changes if mean age at death
differs between two periods or countries although the
absolute differences between individuals’ ages at death
are the same). As to the interquartile range, it violates
the transfer principle (it ignores a change in the distri-
bution of deaths within a given age class if the number
of deaths in that class does not change). For this reason,
the standard deviation will be used as an indicator of
VAD in the analysis below.
The present study extends previous work in three
ways. First, it uses panel data tracing 24 OECD coun-
triesa over the past 46 years, permitting to test the
robustness of the results found by [20]. Second, since
the relative contribution of medical and non-medical
inputs may well change with age, VAD among the
elderly (where rectangularization of the survival curve
has been especially marked, see Figure 2) is examined in
particular. Third, using evidence on the willingness to
pay (WTP) for health risk reduction, WTP values are
calculated for the two countries with the highest HCE
per capita, the United States and Switzerland. These
values are compared with the extra HCE to determine
whether flat-of-the-curve medicine may be still worth-
while thanks to its effect on VAD. However, to address
these research questions we first have to determine
whether the countries of our sample indeed operate (on
average) on the flat-of-the-curve. In sum, this leads to
the following four research questions:
Q1: Are the countries of our sample characterized
by flat-of-the-curve medicine?
Q2: Do medical or non-medical inputs contribute
more to reducing variability of age at death (VAD)?
Q3: Are these effects different for VAD among the
elderly?
Q4: Is flat-of-the-curve medicine wasteful?
Methods
One way to assess the contribution of a set of inputs to
remaining life expectancy at age 60 (LE60) and variability
of age at death (VAD) is by eliminating certain causes of
death from the data (see [17,16], but also [21], and [22]).
However, comparing different countries over time
entails the problem that this contribution may be condi-
tioned by country-specific characteristics (e.g. the type
of health care system). In contrast, econometric techni-
ques designed for panel data permit to control for het-
erogeneity between countries either through fixed or
random effects. In the fixed effects (FE) approach, the
country-specific effects, ci, are included in the set of
independent variables as a set of country-specific dum-
mies. Alternatively, the ci can be netted out by measur-
ing all variables as differences from their country-
specific means. The random effects (RE) approach
assumes the ci to be stochastic, which means they must
be uncorrelated with the independent variables for
unbiased parameter estimation. Both the RE and FE esti-
mation were found to suffer from heteroskedasticity,
reflecting cross-sectional correlation of error terms in
Eqs. (4) and (5) below. Correcting for heteroskedasticity
with a first-order autoregressive error term [AR(1) pro-
cess] and applying the Hausman test we find that RE is
preferred over FE throughout at the 5 percent signifi-
cance level or better.
However, three additional issues need to be clarified.
First, medical and non-medical inputs were found to
influence remaining life expectancy with a lag by [11].
The same may be true for our sample. Alcohol consump-
tion, for instance, likely does not undermine control over
one’s health immediately but rather over the course of
years. Likewise, earlier HCE may also contribute to
higher remaining life expectancy and lower VAD, respec-
tively. As to GDP, it is interpreted as a budget constraint
and an indicator of individual productivity. In principle,
it could influence VAD with a lag as well. However,
lagged GDP caused severe multicollinearity with lagged
HCE, forcing a simplified specification with current GDP.
Based on the Hausman test, we choose an optimal lag
length of 10 years for HCE and ALC in Eq. (4) and 5
years for HCE in Eq. (5), values that seem to be reason-
able in view of earlier research. Second, realizing a health
profile as shown in Figure 1 calls for investment in (the
control of) health over the life-cycle in response to age-
dependent mortality. However, the corresponding health
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production function would require life-cycle measure-
ments of HCE and other inputs, which are not available
internationally at this time.b The third issue is endogene-
ity. Remaining life expectancy and VAD may feed back to
HCE. Countries where individuals live shorter or face
higher uncertainty with regard to longevity may spend
more on HCE than countries where individuals live
longer or face less uncertainty. Such a feedback would
likely occur through the political process, in analogy to
the feedback relationship found by [11]. However, the
Durbin-Wu-Hausman test ([23] and [24]) for endogene-
ity does not reject the null hypothesis of exogeneity of
HCE at the one percent level.
Based on the econometric specification of [20] and the
conventional health production approach (see e.g. [11])
the following specification is estimated (note that the
variables in Eq. (2) are in logarithms):
LE60it = α0 + α1HCEit−10 + α2HCE2it−10 + α3GDPit + α4GDP
2
it
+ α5ALCit−10 + α6ALC2it−10 + ci + γt + uit.
(1)
VADit = β0 + β1HCEit−5 + β2HCE2it−5 + β3GDPit + β4GDP
2
it
+ β5ALCit−10 + β6ALC2it−10 + ci + γt + uit.
(2)
The dependent variables are,
• LE60: Remaining life expectancy at age 60, corre-
sponding to the average actual retirement age.
• VAD: Variability of age at death of country i in
year t measured by the overall sd and the sd above
the modal year, calculated according to Eqs. (4), (5).
Both variables are calculated from period life tables as
follows (this type of life tables is discussed at the begin-
ning of the next section). LE60 is the weighted average
of age at death above 60, x - 60, with weights given by
the number of individuals dying at the respective age,









fx · (x − 60), (3)
where ω is the maximum age in the life table. This
variable will be used to check whether industrial coun-
tries indeed are on the flat-of-the-curve with regard to
HCE (see the section denoted “checking for flat-of-the-
curve medicine”).







fx(x − le)2, (4)
with le symbolizing life expectancy at birth. In keeping
with Figure 1, perfect rectangularization means a vertical
drop of the health (and hence survival) profile. The age
at which the greatest number of a cohort’s members die
approximates best this vertical drop. Therefore, the
standard deviation above the modal year will be used to
measure compression of mortality, which increasingly
occurs at higher ages (see the example of Sweden again
in Figure 1). The sd above the modal year is calculated





fx(x − mode)2. (5)
The independent variables are,
• HCE-5/-10: Total private and public HCE per capita,
nominal but converted in 1,000 USD. Devoting more
resources to health care is expected to enhance con-
trol over health status, and hence higher LE60 and
lower VAD, repectively. Therefore, a1 is predicted to
be positive and b1 to be negative.
• GDP : GDP per capita in 1,000 USD, nominal but
converted in 1,000 USD. This variable first of all
reflects the budget contraint. Now, length of life and
control over one’s health status is quite likely a nor-
mal good, the demand for which increases with aver-
age income, ceteris paribus. Second, however,
average income is importantly determined by labor
productivity. To the extent that non-market and
market productivity develop in a similar way, a
higher value of GDP reflects a population that is bet-
ter able to control their health status. In this way,
GDP also serves as an overall indicator of non-medi-
cal inputs. Both arguments suggest a positive sign
for a3 and a negative sign for b3.
• ALC-10: Annual consumption of pure alcohol in
liters per person above the age of 15. Lower values
indicate a healthier lifestyle implying improved
health and control over health status. Hence, a5 is
predicted to be positive and b5 to be negative.
• ci: A set of country-specific dummies.
• gt: A set of year-specific dummies to control for a
possible time trend.
• uit: A stochastic error term, assumed to be i.i.d.
normal.
Data
Data to compute the dependent variables are obtained
from the [25]. The Human Mortality database provides
two different variants of life tables, cohort and period
life tables. The former represent the mortality experi-
ence of individuals who are born in the same year and
thus are truly comparable. However, cohort life tables
contain complete mortality information only on cohorts
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without any survivors left. By way of contrast, period life
tables show the estimated number of survivors at age x
if a hypothetical birth cohort of 100,000 born today
have the mortality rates that are observed today for peo-
ple at various ages up to x ([25]).c
The overall sd exhibits an almost linear downward
trend between 1960 and 1995 when averaged over 24
OECD countries (see Figure 3). Figure 4 traces the over-
all sd for six selected countries. Interestingly, the rank-
ing between countries changed over time. In 1960, the
Italians, Portuguese, and Japanese faced higher uncer-
tainty of age at death than U.S. citizens (up to 7 years in
terms of sd). However, by 2005 Americans faced consid-
erably higher VAD than the citizens of these countries
(almost 3 years in terms of sd).
The sd above the modal year exhibits a less regular
pattern than the overall sd, mainly due to shifts in the
age with maximum mortality. It remains roughly con-
stant in the 1960s and 70s but has declined since 1980
(see Figure 5). Figure 6 shows that rectangularization at
higher ages differs considerably between the six selected
countries. It has declined for all six countries (except for
the United States); however, the pattern of decline is
again less regular than that of the overall sd.
In sum, the indicators for VAD confirm the findings of
previous studies (see the section “theoretical back-
ground”). They suggest that individuals in industrialized
countries have been exposed to less uncertainty regarding
their longevity (and presumably health status) since the
1960s, although differences between countries and subper-
iods (especially for the sd above the modal year) persist.
The more the question of what may have contributed to
these differential developments gains importance.
Turning to the independent variables, we defined
medical and non-medical inputs drawing on the litera-
ture of the production of health ([7-10], and [11]). Due
to missing values in the OECD health data base only
the following determinants are retained. These are GDP
per capita and alcohol consumption per capita in liters
for the non-medical and health care expenditure per
capita for the medical input. The OECD data is known
for some problems. One of them is national differences
with regard to the delimitation of the health care sector,
resulting in different baskets of services, another the
lack of comparability and precision of health care defla-
tors. In the case of countries such as Switzerland or the
Netherlands, HCE covered by basic health insurance are
termed private HCE although basic insurance is manda-
tory and regulated by the government.d In view of these
difficulties, HCE is not split into private and public HCE
(contrary to [20]). Furthermore, HCE is not deflated
using national price indexes but by the exchange rate
when converting the figures into USD, thus avoiding
PPP indicators that may contain additional measure-
ment errors (see [26]).
Figure 3 Standard deviation of age at death averaged over 24
OECD countries, 1960 to 2005.
Figure 4 Standard deviation for selected countries, 1960 to
2005.
Figure 5 Standard deviation above the modal year averaged
over 24 OECD countries, 1960 to 2005.
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The sample comprising the 24 countries is character-
ized in Table 1 below. As to sd, the indicator of VAD, it
decreases from 19.34 years in 1960 to 14.74 years in
2005. Decomposition of sd suggests that within-country
differences (sdw) are rather more important than
between-country ones (sdb), indicating that decreases
over time are the primary source of variation. Turning
to the independent variables, one observes slower
growth of HCE and GDP in recent years. Whereas total
HCE and GDP per capita increased by factors of 13 and
8, respectively between 1960 and 1983, these factors
decreased to 4.5 and 3.5 between 1983 and 2005. Inter-
estingly, alcohol consumption per capita (ALC)
increased first but has been diminishing after reaching a
peak in the mid 1970s. As to the decomposition of the
standard deviation of the independent variables, varia-
tion over time again exceeds the between standard
deviation (sdb), except for alcohol consumption.
Results and discussion
Checking for flat-of-the-curve medicine
Table 2 presents RE estimation results for (arithmetic)
LE60. This choice of dependent variable permits a com-
parison with [11], who estimated a similar specification
for women and men separately using a different samplee.
In general, the estimated coefficients roughly correspond
with these previously estimated values (see column
entitled female of Table 2). In keeping with these earlier
estimates, HCE exhibits decreasing marginal returns.
With regard to remaining life expectancy, the critical
value of HCE beyond which its marginal effect ceases to
be positive can be put at USD 2,116.f With a mean
value of USD 3,436 as of 2005 OECD countries on aver-
age are well within the flat-of-the-curve range. There-
fore, as to research question Q1 stated at the beginning
of this paper, we can conclude that the countries in our
sample operate on the flat-of-the-curve.
However, this traditional view on the production of
health may well neglect the impact of HCE on the
uncertainty surrounding life expectancy. This is
addressed in the following section.
Variability of age at death as the dependent variable
Table 3 presents (double-log) RE estimation results for
sd and sdmode, the two indicators of variability of age at
death emphasized here. For a comparison with Table 2,
elasticities of LE60 evaluated at the means are provided
in the column entitled Table 2. Three things are note-
worthy. First, the same inputs that were found to
increase (decrease) the expected value are estimated to
decrease (increase) the variability of life expectancy. Sec-
ond, whereas GDP is more effective than HCE in
increasing the expected value (see fifth column), it tends
to be less effective in reducing its variability of longevity.
Third, HCE exhibits decreasing returns also as an
instrument for controlling variability of health status.
Turning to the detailed estimation results for the
overall standard deviation in Table 3, we find HCE-5 to
be significant and with the predicted negative sign. Eval-
uated at the mean values, a 10 percent increase of HCE
Figure 6 Standard deviation above the modal year for selected
countries, 1960 to 2005.
Table 1 Descriptive statistics of variables, selected years
Variable Mean 1960 1983 2005 sdo sdb sdw N
LE60 19.67 17.63 19.51 22.85 1.99 1.06 1.69 997
SD 16.81 19.34 16.44 14.74 1.76 0.97 1.49 1,102
SDmode 4.17 4.34 4.33 3.81 0.39 0.19 0.35 1,102
HCE 1,283 60.25 792.28 3,436 1,187 636.22 1068 838
GDP 13,866 1,341 10,287 35,782 11,903 7,787 10,780 965
ALC 10.62 7.87 11.81 9.41 3.66 3.27 1.78 1,003
Note: The countries included are Australia, Austria, Belgium, Canada, Czech
Republic, Denmark, Finland, France, Germany, Hungary, Iceland, Italy, Japan,
Luxembourg, Netherlands, New Zealand, Norway, Portugal, Slovak Republic,
Spain, Sweden, Switzerland, United Kingdom, United States.
Table 2 Determinants of remaining life expectancy at age
60 (total population), 1960-2005
LE60 Coef. z P>z Coef. (female)
a
HCE-10 0.842 2.49 0.013 2.045**
HCE2-10 -0.199 -1.99 0.046 -0.565**
GDP 0.041 2.06 0.040 0.122**
GDP2 -0.001 -2.11 0.036 -0.004**
ALC-10 -0.039 -0.60 0.546 -0.043
ALC2-10 -0.002 -1.09 0.276 0.002






Note: **p < 0.01.aEstimates for females from [11].
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5 years earlier is estimated to reduce the current stan-
dard deviation of age at death by
10 · (−0.072 + 2 · 0.005 · lnHCE−5) = 0.42 percent. The
effect of non-medical inputs is in the same range, with
an increase of GDP by 10 percent associated with a
decrease of variability by 0.66 percent (neglecting the
insignificant squared term). As predicted, an unhealthy
lifestyle proxied by ALC-10 seems to weaken control
over health status. An earlier increase of alcohol con-
sumption by 10 percent increases VAD by an estimated
0.49 percent (again neglecting the squared term).
For the standard deviation above the modal year, the
results are quite different. Only alcohol consumption is
significant at the 5 percent level, with a similar esti-
mated effect. A 10 percent increase 10 years earlier goes
along with a 10 · (0.210 − 2 · 0.046 · lnALC−10) = 0.26
percent increase of the standard deviation above the
modal year. Especially at older ages, unhealthy lifestyle
in the past seems to induce a lack of control over health
status. Still, the insignificant coefficients pertaining to
HCE come as a surprise because according to e.g. [8],
health status of the elderly (measured by their remaining
life expectancy) appears to have strongly benefited from
pharmaceutical innovation in particular. The apparent
contradiction may be resolved by referring back to Fig-
ure 5. There, it appears that HCE may have influenced
variability of age at death among the elderly only in
recent years, possibly due to medical progress for the
treatment of old-age diseases (e.g. circulatory and
respiratory diseases and cancers; for some evidence, see
[27]). The graph suggests reestimation of the model for
the time period between 1983 to 2005. Results are pre-
sented in Table 4 below.
Now, HCE-5 turns out to be significant at the 5 per-
cent level, with a 10 percent increase serving to reduce
variability of age at death by an estimated 0.56 percent.
Almost the same magnitude is found for GDP. How-
ever, ALC-10 is found to be insignificant. Also note
that the estimated coefficients pertaining to HCE and
GDP cannot be distinguished from those for the over-
all sd in Table 2. Therefore, as to the research ques-
tion Q2, we can conclude that both medical and non-
medical inputs contribute to the observed reduction in
VAD, and to a comparable extent. As to research
question Q3, the answer depends on the period of
observation. For the period as a whole (1960 to 2005),
the elderly seem to differ in that VAD above the
modal year cannot be related to either HCE or GDP.
However, from the mid-1980s on, these two variables
have effects that are comparable to those on the gen-
eral population.
Is flat-of-the-curve medicine wasteful?
In the previous section, evidence was presented to
the effect that many OECD countries presently are
characterized by flat-of-the-curve medicine if the
marginal contribution of HCE to remaining life
expectancy is accepted as the criterion. However,
according to the estimation results presented in
Tables 3 and 4, HCE does contribute to reduced
uncertainty with regard to health status. In the pre-
sent context, this effect is valued using the risk pre-
mium an individual would be willing to pay for
reducing the risk of premature death indicated by the
variability of age at death (VAD).
Theoretically, the risk premium can be derived from
the following equality condition that makes an indivi-
dual indifferent between the certain health status A after
deduction of the premium ρ(X˜) and the risky health
profile B of Figure 1. In Eq. (6) below, u[HA] denotes
the certain utility associated with certain health A (in
money equivalent) and EU, expected utility associated
Table 3 Determinants of variability of age at death,
1960-2005
sd Table 2 sdmode
VAD
Coef. z P>z ε
LE60
Coef. z P>z
HCE-5 -0.072 -3.09 0.002 0.032 -0.019 -0.27 0.788
HCE2-5 0.005 2.65 0.008 0.002 0.28 0.783
GDP -0.066 -1.99 0.046 0.041 -0.006 -0.03 0.980
GDP2 0.004 0.94 0.345 0.001 0.06 0.955
ALC-10 0.049 1.29 0.198 -0.029 0.210 2.17 0.030
ALC2-10 0.017 1.87 0.061 -0.046 -1.97 0.049
constant 3.435 11.47 0.000 1.321 1.43 0.154
rhoar 0.786 0.237




Table 4 Determinants of variability of age at death
above the modal year (sdmode), 1983-2005
Explanatory variable Coef. z P>z
HCE-5 -0.056 -2.49 0.013
HCE2-5 0.005 0.47 0.639
GDP -0.058 -2.97 0.001
GDP2 0.002 0.15 0.881
ALC-10 0.061 0.28 0.776
ALC2-10 -0.017 -0.36 0.719
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with risky health B, which is composed of HA and a
small variation X˜ of health status,
u[HA − ρ(X˜)] = EU[HA + X˜]. (6)
Applying Taylor approximations to both sides and sol-
ving for ρ(X˜), one obtains the Arrow-Pratt formula in




σ 2x · RA, (7)
with RA := − u
′′[HA]
u′[HA]
defining the coefficient of absolute
risk aversion. The risk premium therefore is given by
the product of (one half of) the variance of health status,
σ 2x , and the coefficient of absolute risk aversion. Now,
risk aversion with regard to a variation in health may
well differ from risk aversion with regard to wealth.
Therefore, it is important to use an estimate that has a
close connection to health. The one by [29] qualifies
because it is derived from the choice of health insur-
ance. His value of RA is 3·10
-3; in the interest of a con-
servative estimate of the risk premium, we use a value
of RA equal to 10
-4. The next step is to express the var-
iance of length of life (as an indicator of health), σ 2x , in
monetary units. This will be done for the two countries
that devote very high per-capita amounts to health care
and therefore likely constitute two extreme cases of flat-
of-the-curve medicine, the United States and Switzer-
land. The United States Environmental Protection
Agency ([30]) has been using a value of USD 6.3 mn.
per statistical life in its cost-benefit analyses since 1999.
[31] estimate an average value of CHF 12.5 mn. for
Switzerland based on labor market data as of 1995. Tak-
ing the base year 2000 and an interest rate of 3 percent,
this amounts to a value of a statistical life of USD 6.5
mn. for the United States and USD 8.7 mn. for Switzer-
land (with and an exchange rate of 1CHF = 0.6USD).
Given that the two estimates above relate to statistical
lives and hence are the result of a linear extrapolation of
small changes in survival probabilities, it is also admissi-
ble to interpret them as linear extrapolations of a
change of one year of life expectancy. With average life
expectancies of 73.8 years (United States) and 76.2
(Switzerland) respectively, one statistical year of life is
worth USD 87,927 in the United States and USD
114,102 in Switzerland. Based on a utility-theoretic
model of preferences over length of life, [13] predicts
that an individual would be willing to trade one-half a
year of additional life expectancy against a reduction of
uncertainty by one standard deviation. Therefore, a
change of one sd in age at death can be valued at some
USD 43,963 (United States) and USD 57,051 (Switzer-
land), respectively. According to the estimation results
presented in Table 3 a 10 percent increase of HCE is
estimated to reduce the sd by 0.42 percent, i.e. from
18.01 to 17.93 years in the US and from 16.24 to 16.17
in Switzerland.
Inserting these estimates into Eq. (7) we obtain the




((18.01)2 − (17.93)2)(4.40 · 104)2 · 10−4 = 2.78 · 105(United States) (8)
1
2
((16.24)2 − (16.17)2)(5.71 · 104)2 · 10−4 = 3.25 · 105(Switzerland) (9)
Distributed over 73.8 years this becomes a WTP value
for the United States of USD 3,771 and USD 4,261 for
Switzerland. The last step concerns the marginal cost.
In 2000, the United States spent USD 4,704 per capita
on health care and Switzerland, USD 3,529. Hence, 10
percent more HCE amounts to USD 470 and USD 353,
respectively. The comparison with the estimates in Eqs.
(8) and (9) clearly shows that in both countries, WTP
for increased certainty with regard to age at death
exceeds their marginal cost in terms of HCE. Therefore,
one can answer Q4 by concluding that even if HCE
should not prolong life anymore, it may be worth its
cost as “real insurance” reducing the variability of health
status.
Conclusions
This study addresses an issue that has been overlooked
in the production of health literature with its emphasis
on flat-of-the-curve medicine. For risk-averse indivi-
duals, not only the level of health but also its variability
is important. However, improved control over health
status is reflected in an increased rectangularization of
the survival curve, indicating a reduced variability of age
at death (VAD). Since this rectangularization can indeed
be observed in OECD countries, this raises four research
questions. Are the countries of our sample characterized
by flat-of-the-curve medicine (Q1)? Do medical or non-
medical factors contribute more to reducing VAD (Q2)?
Do these effects differ among the elderly, where rectan-
gularization has been prominent (Q3)? Is flat-of-the-
curve medicine wasteful (Q4)?
The standard deviation (sd) of age at death serves as
an indicator of overall uncertainty concerning health
status and the sd above the modal year (where the num-
ber of deaths in adulthood reaches its maximum) as an
indicator of uncertainty surrounding health status
among the elderly. Between 1960 and 2005 both mea-
sures decreased for the 24 OECD countries sampled,
pointing to reduced VAD. However, sd above the modal
year began to fall in the early 1980s only. These two
indicators are related to HCE as a proxy of medical
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inputs to the production of health and to GDP and alco-
hol consumption as a proxy of non-medical ones. Based
on a specification that takes account of hidden heteroge-
neity through random effects, the four research ques-
tions can be answered as follows.
Q1: According to our estimates the critical value of
HCE beyond which its marginal effect ceases to be
positive can be put at USD 2,116. With a mean
value of USD 3,436 as of 2005, the OECD countries
of our sample are on average well within the flat-of-
the-curve range.
Q2: The reduction of VAD (indicating better control
over health status) is importantly due to both, HCE
and GDP.
Q3: Significant effects of HCE and GDP on VAD
among the elderly are found for the time period
between 1983 to 2005 only, of a magnitude compar-
able to Q2.
Q4: Comparing the marginal cost in terms of HCE
with the willingness-to-pay values for the United
States and Switzerland, we find that the benefits in
terms of reduced VAD exceed the extra cost. There-
fore, flat-of-the-curve medicine may be worthwhile
as “real insurance” serving to reduce uncertainty of
health status.
However, several limitations of this study need to be
pointed out. First, variability of health status as experi-
enced by individuals is only crudely measured by cross-
sectional measures such as the standard deviation of age
at death. Tracking individual’s health status over time
would be preferable, but availability of panel data would
restrict the analysis to a few countries only. Second,
medical and especially non-medical inputs to the pro-
duction of health are not very well captured by HCE
and GDP and alcohol consumption per capita, respec-
tively. Unfortunately, measures of education and other
indicators of lifestyle do not date back sufficiently far
for many OECD countries. Third, we used a coefficient
of absolute risk aversion derived from U.S. data. Its
value likely differs between countries.
However, the findings on the whole do suggest that
variability of health status can be influenced. This has
important implications. First, reduced uncertainty about
age at death likely has been modifying the decisions
especially of older individuals concerning savings, con-
sumptions, and the purchase of life and long-term care
insurance. Quite generally, it helps risk-averse indivi-
duals to optimize lifetime consumption, permitting
them to reduce precautionary saving (see [32] and [33]).
Second, knowing the extent and determinants of varia-
bility of health status enables insurers and reinsurers to
calculate more accurate values of the financial risk they
are exposed to and expected to face in the future in dif-
ferent countries. Finally, our study suggests comple-
menting the economic evaluation of medical
interventions (such as cost-utility or cost-effectiveness
analysis) with possible reductions in the uncertainty of
outcomes.
Endnotes
aThese are Australia, Austria, Belgium, Canada, Czech
Republic, Denmark, Finland, France, Germany, Hungary,
Iceland, Italy, Japan, Luxembourg, the Netherlands, New
Zealand, Norway, Portugal, Slovak Republic, Spain, Swe-
den, Switzerland, United Kingdom, and the United
States.
bWe owe this important point to an anonymous
referee.
cA disadvantage of period life tables is that they are
based on one-year age intervals and that it is assumed
that infants born today will experience the same mortal-
ity risks over their lifetimes as do the various age groups
in the current population (see [18]). In times of decreas-
ing mortality rates, period life tables underestimate life
expectancy.
dE.g. premiums for the basic mandatory coverage are
not risk-rated.
eThey included consumption of kilocalories per capita
as an additional lifestyle variable, which however turned
out to be not significant.
fFrom Table 2, one obtains the critical value beyond
which e(LE, HCE) decreases: ∂LE∂HCE = 0.842 − 2 · 0.199HCE = 0.
This yields HCE = 2.116 or 2,116 USD respectively,
which is in the same range as the critical value esti-
mated in [11].
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